Vertex Pharmaceuticals Inc VRTX

NASDAQ US Health Care Biotechnology

$477.10 ▼ -0.96% ($-4.60)

Index member: S&P 500

📅 Earnings This Week

Open $480.67

Prev Close $481.70

Day Range $469.87 – $480.67

52W Range $362.50 – $533.67

Market Cap $121.16B

P/E (TTM) 27.78

Beta 0.30

EPS (TTM) $16.87

📋 Company Profile

Industry	Biotechnology
Sector	Health Care
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	1991-07-24
Shares Out.	253,810,000
Website	vrtx.com/ ↗
Phone	16173416393
Employees	6,400
Revenue	$2.99B
Gross Profit	$2.59B
Net Income	$1.03B
Free Cash Flow	$3.71B
Total Assets	$26.48B
Total Liabilities	$7.12B
Equity	$19.36B

About Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Vertex Pharmaceuticals Inc is a publicly traded company under the ticker symbol VRTX on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.